Thursdays at Abnormal Returns are all about startup and venture capital links. You can check out last week’s links including a look at academic research on startup accelerators.
Quote of the Day
"To be successful in business does not mean changing the world. It means meeting a need (regardless of size) well and dependably over time."
(Dave Schools)
TV talk
- Life after Shark Tank: three startups weigh in on their experience after their appearances on the show. (m.signalvnoise.com)
- What lessons you can learn from Marcus Lemonis' reality show "The Profit." (marginalrevolution.com)
Entrepreneurs
- How bootstrapping will make you a better founder. (medium.com)
- The downside of quitting a corporate gig for the startup life. (medium.com)
- Four lies that entrepreneurs tell themselves. (thinkgrowth.org)
VC
- It's no surprise to VCs, but the process of capital formation is becoming increasingly private. (wsj.com)
- Not every technological breakthrough is fit for the VC-model of funding. (hbr.org)
- What are some alternatives to traditional pitch decks. (avc.com)
- How to prove you market is big enough for VC. (bettereveryday.vc)
VC careers
- For anyone getting into venture capital, getting "into the carry" is the key, but isn't easy. (blog.semilshah.com)
- There is no single path into getting a job in venture capital. (blog.semilshah.com)
Companies
- Eventbrite and Upwork are planning to go public. (wsj.com)
- Does Lyft now need to buy its own bike-sharing company? (blog.semilshah.com)
- Which unicorns are growing and which are shrinking, according to headcount? (priceonomics.com)
Quotes
- Tom Tunguz, "Cash today empowers the holder to buy options. The more cash today, the broader the option portfolio available to the CEO. The CEO is the asset allocator in chief. He or she decides which options to buy. The more cash the company has, the more options are available." (tomtunguz.com)
- Kate Preston McAndrew, "The best investors are more interested in how you think than what you know." (blog.bolt.io)
- Nir Eyal, "Most people, including many professional investors, tend to put new products into one of two categories: vitamins or painkillers." (medium.com)
